DOCSLIB.ORG

2018 Formulary Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2018 Formulary Drug List 2018 Formulary Drug List For Small Groups and Large Groups GlobalHealth, Inc. 701 NE 10th Street, Suite 300 Oklahoma City, OK 73104-5403 MGDF18 Lists Updated 11/2017 www.GlobalHealth.com/commercial HELPFUL NUMBERS Plan Issuer: Medication Prior Authorizations: GlobalHealth, Inc. [email protected] PO Box 2393 918.878.7361 Oklahoma City, OK 73101-2393 Mail Claims to: GlobalHealth Customer Care, Language Magellan Rx Management, LLC Assistance, and Disease Management: PO Box 85042 [email protected] Richmond, VA 23261-5042 405.280.2964 (local) 1.877.280.2964 (toll-free) Mail Order Pharmacy: 711 (TTY) Magellan Rx Management, LLC Monday – Friday, 9 a.m. – 5 p.m. Central 1.800.424.1789 (toll-free) www.GlobalHealth.com/commercial 711 (TTY) P.O. Box 620968 Behavioral Health and Substance Use: Orlando, FL 32862 [email protected] 405.280.2964 (local) 24/7 Nurse Help Line: 1.877.280.2964 (toll-free) Information Line 711 (TTY) 1.877.280.2993 (toll-free) Monday – Friday, 9 a.m. – 5 p.m. Central www.GlobalHealth.com/commercial GlobalHealth Compliance Officer: 1.877.280.5852 (toll-free) Pharmacy Benefits Manager: 405.280.5852 Magellan Rx Management, LLC [email protected] Customer Service 1.800.424.1789 (toll-free) GlobalHealth Privacy Officer: 711 (TTY) 405.280.5524 [email protected] i IMPORTANT INFORMATION This formulary applies to Members who enrolled through an employer in any of the following Plans: Platinum Plan 1 without Dental Gold Plan 1 with Dental Gold Plan 1 without Dental Standard Plan Member Materials Your comprehensive Member handbook has three booklets. Each one has a different purpose. These documents are important legal documents. Keep them in a safe place. Booklet Purpose Member Handbook Tells you about your benefits. – the name of your o What benefits are covered and how much you will pay. Member Handbook o How they are covered (including limitations and exclusions). will depend on o How to use them. which Plan you enrolled in Physicians and Lists our Network of doctors, Facilities, and pharmacies. Health Providers Tells you if a Facility is preferred or not. Directory (“Provider Directory”) Formulary Drug Lists drugs we cover. List for Small Tells you what Tier a drug is in. Groups and Large Tells you if there are any rules to getting a drug. Groups (“Drug Formulary” or “Formulary”) Member materials are available on our website. Contact Customer Care for printed copies at no charge. But, be aware that the most current Drug Formulary and Provider Directory lists are on the website. When this document says “we”, “us”, or “our”, it means GlobalHealth, Inc. Words or phrases that start with a capital letter are defined in the Member Handbook glossary. For specific questions about your coverage, please call the phone number printed on your Member ID card. ii Preferred Drugs Preferred drugs are listed in this Drug Formulary. Drugs on the list are selected based on quality (effectiveness and safety) as well as cost-effectiveness. Doctors and pharmacists have worked together to develop the Formulary, which includes generics and brand name drugs that are approved by the U. S. Food and Drug Administration (“FDA”). For the Member: Generic drugs contain the same active ingredients in the same amounts as brand name products. However, they may be a different color, shape, or size. For the physician: Please prescribe preferred products and allow generic substitutions when medically appropriate. Thank you. THIS DOCUMENT LIST IS EFFECTIVE AS OF THE DATE ON THE COVER. THIS LIST IS SUBJECT TO CHANGE. You may find the most current list, including any Utilization Management requirements, on our website. Contact Customer Care for printed copies. iii TIER DESCRIPTION 0 Health Care Reform Health Care Reform 1 Generics 2 Preferred Brands 3 Non-Preferred Brands 4 Specialty Drug TYPE DESCRIPTION There is a limit on the amount of this drug that is covered per QL Quantity Limit prescription, or within a specific time frame. Your provider is required to get prior authorization before you fill PA Prior Authorization your prescription, which ensures appropriate use of the selected drug. Without prior approval, we may not cover this drug. In some cases, you may be required to first try certain drugs to treat ST Step Therapy your medical condition before you move up a “step” to other drug options. GL Gender Limit This prescription drug is restricted for a single gender. This prescription drug may only be covered if you meet the AL Age Limit minimum or maximum age limit. C Custom This drug has unique restrictions. Specialty drugs are high-cost drugs used to treat complex or rare S Specialty Drug conditions. Some examples of the diseases include; multiple sclerosis, rheumatoid arthritis, hepatitis C, and hemophilia. This medication is not on our drug list. Click on the THERAPEUTIC MED Medical Drug CLASS or sub class to find covered alternative medications. If you have questions, please contact member services. The Affordable Care Act (ACA) requires certain preventive generic HCR Health Care Reform Products products to be covered at zero dollar copay. This does not include plans that are grandfathered. PAGE 1 LAST UPDATED 10/2017 PS Preferred Specialty Preferred Specialty. Generic drugs available at the lowest cost. Please note the specific strengths and dosage forms; other strengths and/or dosage forms LCG Low Cost Generic of these products would be subject to the standard generic Cost- share. PAGE 2 LAST UPDATED 10/2017 LIST OF COVERED PRESCRIPTION MEDICATIONS PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS ADRENERGIC AGENTS ALPHA AND BETA ADRENERGIC AGONIST(RESPR) QL 2 / fill ADRENACLICK 3 PA ADRENALIN 3 ADYPHREN 3 QL 2 / fill ADYPHREN AMP 3 QL 2 / fill ADYPHREN AMP II 3 QL 2 / fill ADYPHREN II 3 QL 2 / fill QL 2 / fill AUVI-Q 3 PA ephedrine hcl 3 ephedrine sulfate powder 3 epinephrine (0.15 mg auto-injct, 0.3 mg auto-inject) 1 QL 2 / fill epinephrine (base powder, powder) 3 epinephrine (1 mg/ml ampul, 1 mg/ml vial) 1 epinephrine bitartrate 3 epinephrine hcl 3 EPINEPHRINESNAP-V 3 QL 2 / fill QL 2 / fill EPIPEN 3 PA QL 2 / fill EPIPEN 2-PAK 3 PA QL 4 / fill EPIPEN JR 2-PAK 3 PA PAGE 3 LAST UPDATED 10/2017 PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS EPISNAP 3 QL 2 / fill EPY 3 QL 2 / fill QL 40/ day HYCOFENIX 3 AL At least 18 yrs old pseudoephedrine hcl 3 racepinephrine hcl 3 QL 20 / day REZIRA 3 AL At least 18 yrs old NON-SELECT.BETA-ADRENERGIC AGONT(RESPIR) isoproterenol hcl powder 3 ISUPREL 3 SELECT.BETA-2-ADRENERGIC AGONIST(RESPIR) ADVAIR DISKUS 2 QL 2 / day ADVAIR HFA 2 QL 0.4 / day QL 0.04 / day AIRDUO RESPICLICK 3 PA AL At least 12 yrs old albuterol sulfate powder 3 albuterol 5 mg/ml solution 1 LCG albuterol sulfate (sul 0.63 mg/3 ml sol, sul 1.25 mg/3 ml sol, sulf 2 mg/5 ml syrup, 2.5 mg/0.5 ml sol, sul 2.5 mg/3 ml soln, sulfate 2 mg tab, sulfate 4 mg tab, sulfate er 4 mg tab, sulfate er 1 8 mg tab) ANORO ELLIPTA 2 QL 2 / day QL 1 / day ARCAPTA NEOHALER 3 ST QL 0.357 / day BEVESPI AEROSPHERE 3 ST PAGE 4 LAST UPDATED 10/2017 PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS BREO ELLIPTA 2 QL 2 / day BROVANA 3 QL 4 / day COMBIVENT RESPIMAT 2 QL 0.267 / day QL 0.434 / day DULERA 3 PA QL 0.04 / day fluticasone-salmeterol 1 AL At least 12 yrs old FORADIL 3 QL 3 / day formoterol fumarate (micro pwdr, powder) 3 ipratropium-albuterol 1 levalbuterol concentrate 1 levalbuterol hcl (100% powder, powder) 3 levalbuterol hcl (0.31 mg/3 ml sol, 0.63 mg/3 ml sol, 1.25 mg/3 ml sol) 1 QL 1.5 / day levalbuterol tartrate hfa 3 PA metaproterenol sulfate powder 3 metaproterenol sulfate (10 mg tablet, 10 mg/5 ml syr, 20 mg tablet) 1 PERFOROMIST 3 QL 120 / 30 days PROAIR HFA 2 QL 0.8 / day QL 0.07 / day PROAIR RESPICLICK 2 AL At least 12 yrs old QL 0.6 / day PROVENTIL HFA 3 PA SEREVENT DISKUS 2 QL 2 / day PAGE 5 LAST UPDATED 10/2017 PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS QL .144 / day STRIVERDI RESPIMAT 2 ST SYMBICORT 2 QL 0.4 / day terbutaline sulfate powder 3 terbutaline sulfate (2.5 mg tab, 5 mg tab) 1 LCG terbutaline sulf 1 mg/ml vial 1 QL 2 / day UTIBRON NEOHALER 3 ST AL At least 18 yrs old VENTOLIN HFA 2 QL 1.5 / day VOSPIRE ER 3 XOPENEX 3 XOPENEX CONCENTRATE 3 QL 1.5 / day XOPENEX HFA 3 PA ALPHA-ADRENERGIC BLOCKING AGENT(SYMPATH) NON-SEL.ALPHA-1-ADRENERGIC BLOCKING AGTS CARDURA 3 QL 1 / day CARDURA XL 3 ST doxazosin mesylate powder 3 doxazosin mesylate (1 mg tab, 2 mg tab, 4 mg tab, 8 mg tab) 1 MINIPRESS 3 prazosin hcl (1 mg capsule, 2 mg capsule, 5 mg capsule) 1 prazosin hcl powder 3 terazosin hcl 1 PAGE 6 LAST UPDATED 10/2017 PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS NON-SEL.ALPHA-ADRENERGIC BLOCKING AGENTS CAFERGOT 3 D.H.E.45 3 DIBENZYLINE 3 dihydroergotamine mesylate (1 mg/ml am, 1 mg/ml vl) 1 dihydroergotamine powder 3 dihydroergotamine 4 mg/ml spry 1 QL 8 / 30 days ergoloid mesylates powder 3 ergoloid mesylates 1 mg tab 1 ERGOMAR 3 ergotamine tartrate 3 ergotamine-caffeine 1 methysergide maleate 3 MIGERGOT 3 MIGRANAL 3 QL 8 / 30 days phenoxybenzamine hcl 10 mg cap 1 phenoxybenzamine hcl powder 3 phentolamine mesylate powder 3 phentolamine 5 mg vial 1 phentolamine-alprostadil 1 SELECTIVE ALPHA-1-ADRENERGIC BLOCK.AGENT QL 1 / day alfuzosin hcl er 1 GL Male carvedilol 1 COREG 3 COREG CR (CR 10 MG CAPSULE, CR 20 MG CAPSULE, CR 40 MG QL 2 / day 3 CAPSULE) ST PAGE 7 LAST UPDATED 10/2017 PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS QL 1 / day COREG CR 80 MG CAPSULE 3 ST QL 1 / day dutasteride-tamsulosin 1 GL Male FLOMAX 3 QL 2 / day QL 1 / day JALYN 3 GL Male labetalol hcl powder 3 labetalol hcl (100 mg tablet, 200 mg tablet, 300 mg tablet) 1 QL 1 / day RAPAFLO 2 GL Male tamsulosin hcl 1 QL 2 / day QL 1 / day UROXATRAL 3 GL Male ANALGESICS AND ANTIPYRETICS ANALGESICS AND ANTIPYRETICS, MISC.
Load more

Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Vitiligo Treatment
    ISSN 2320-5407 International Journal of Advanced Research (2014) Journal homepage: http://www.journalijar.com INTERNATIONAL JOURNAL OF ADVANCED RESEARCH Depigmentation Therapy for Vitiligo: Results from a National Survey Dissertation submitted to Libyan International Medical University In partial fulfillment of the requirements For the award of the degree of Bachelor of Pharmacy BY Makpula Abdelaziz Tarhuni Aisha Ali Derbash Under The Guidance of Dr. Salma Bukhatwa 1 ISSN 2320-5407 International Journal of Advanced Research (2014) Declaration This is to certify that research work embodied in this thesis entitled "Depigmentation therapy of vitiligo: Results from a national survey" has been carried out by us under supervision of Dr. Salma Bukhatwa. Makpula Abdelaziz Tarhuni ................................................... Aisha Ali Derbash ...................................................... 2 ISSN 2320-5407 International Journal of Advanced Research (2014) Abstract Vitiligo is a chronicpigmentarydisorderthat causes the loss of skin color in blotches. Vitiligo happens because of destruction of melanocytes. Classification of vitiligo according to distribution of the lesions is of practical importance usually for assessing the prognosis of the disease. Repigmentation therapyfor vitiligo includes corticosteroids, topical and oral antioxidants, topical calcineurin inhibitors, phototherapy and laser therapy. Depigmentation therapy can be beneficial as alternative therapy for extensive vitiligo patients. Depigmentation therapyof vitiligo
    [Show full text]
  • 2020 Welldyne Formulary.Pdf
    LEGEND TIER DESCRIPTION 1 Preferred Generics 2 Non-Preferred Generics 3 Preferred Brands 4 Non-Preferred Brands 5 Preferred Specialty 6 Non-Preferred Specialty TYPE DESCRIPTION There is a limit on the amount of this drug that is covered per QL Quantity Limit prescription, or within a specific time frame. You (or your physician) are required to get prior authorization before PA Prior Authorization you fill your prescription for this drug. Without prior approval, we may not cover this drug. In some cases, you may be required to first try certain drugs to treat ST Step Therapy your medical condition before we will cover another drug for that condition. This prescription drug may only be covered if you meet the minimum AL1 Age Limit or maximum age limit. LA Limited Access This prescription drug is limited to certain pharmacies. Specialty drugs are high-cost drugs used to treat complex or rare S Specialty Drug conditions, such as multiple sclerosis, rheumatoid arthritis, hepatitis C, and hemophilia. PAGE 1 LAST UPDATED 01/2020 LIST OF COVERED PRESCRIPTION MEDICATIONS PRODUCT DESCRIPTION TIER LIMITS & RESTRICTIONS ADHD/ANTI-NARCOLEPSY /ANTI-OBESITY/ANOREXIANT AGENTS ADHD/ANTI-NARCOLEPSY/ANTI-OBESITY/ANOREXIANTS ADDERALL 4 AL1 Up to 25 yrs old ADDERALL XR 4 AL1 Up to 25 yrs old QL 30 / 30 day(s) ADHANSIA XR 4 AL1 Up to 25 yrs old QL 30 / 30 Days ADIPEX-P 4 PA QL 300 / 30 day(s) ADZENYS ER 4 AL1 Up to 25 yrs old QL 30 / 30 Days ADZENYS XR-ODT 4 AL1 Up to 25 yrs old QL 300 / 30 day(s) AMPHETAMINE ER 4 AL1 Up to 25 yrs old QL 180 / 30 day(s) amphetamine
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • United States Patent (19) 11 Patent Number: 4,765,973 Heller 45 Date of Patent: Aug
    United States Patent (19) 11 Patent Number: 4,765,973 Heller 45 Date of Patent: Aug. 23, 1988 54) POLYMERS CONTAINING PEN DANT ACD Assistant Examiner-M. L. Moore FUNCTIONALITIES AND LABILE Attorney, Agent, or Firm-Manfred Polk; Michael C. BACKBONE BONDS Sudol (75) Inventor: Jorge Heller, Woodside, Calif. 57 ABSTRACT Assignee: Merck & Co., Inc., Rahway, N.J. The instant invention is directed to a polymer with at 73 least one labile backbone bond per repeat unit and at (21) Appl. No.: 915,348 least one pendant acid functionality per thousand repeat 22 Filed: Oct. 6, 1986 units. The instant invention is also directed to a controlled Related U.S. Application Data release device which comprises: (A) a polymer with at least one labile backbone bond (62) Division of Ser. No. 68,002, Jun. 6, 1984, Pat. No. per repeat unit and at least one pendant acid func 4,639,366. tionality per thousand repeat units; and 51 Int. Cl'.............................................. A61K 31/74. (B) a beneficial substance incorporated within or 52) U.S. C. ....................................... 424/486; 424/78 surrounded by the matrix of said polymer. (58) Field of Search ........................ 424/19, 20, 22, 78 Primary Examiner-John Kight 3 Claims, No Drawings 4,765,973 1. 2 Tri- and higher hydroxyl functional polyols may be POLYMERS CONTAINING PEN DANT ACID used, which will result in crosslinked polymers. FUNCTIONALTES AND LABLE BACKBONE Any polymer containing at least one acid labile back BONDS bone bond per repeat unit (preferably two per repeat 5 acid unit) may be used to react with the polyol contain This is a division of application Ser.
    [Show full text]
  • Demecarium Bromide/Homatropine 1881
    Demecarium Bromide/Homatropine 1881 Dyflos (BAN) junctival injection of pralidoxime has been used to reverse severe ocular adverse effects. Supportive treatment, including assisted DFP; Difluorophate; Di-isopropyl Fluorophosphate; Di-isopro- ventilation, should be given as necessary. CH3 pylfluorophosphonate; Fluostigmine; Isoflurofato; Isoflurophate. Di-isopropyl phosphorofluoridate. To prevent or reduce development of iris cysts in patients receiv- N ing ecothiopate eye drops, phenylephrine eye drops may be giv- C6H14FO3P = 184.1. en simultaneously. CAS — 55-91-4. ATC — S01EB07. Precautions ATC Vet — QS01EB07. As for Neostigmine, p.632. For precautions of miotics, see also OH under Pilocarpine, p.1885. In general, as with other long-acting anticholinesterases, ecothiopate should be used only where ther- O apy with other drugs has proved ineffective. Ecothiopate iodide CH3 should not be used in patients with iodine hypersensitivity. O O H3C O Interactions P CH3 As for Neostigmine, p.632. The possibility of an interaction re- O F mains for a considerable time after stopping long-acting anti- Homatropine Hydrobromide (BANM) CH3 cholinesterases such as ecothiopate. Homatr. Hydrobrom.; Homatropiinihydrobromidi; Homatropi- Pharmacopoeias. In US. Uses and Administration na, hidrobromuro de; Homatropine, bromhydrate d’; Homatro- USP 31 (Isoflurophate). A clear, colourless, or faintly yellow liq- Ecothiopate is an irreversible inhibitor of cholinesterase; its ac- pin-hidrobromid; Homatropinhydrobromid; Homatropin-hydro- uid. Specific gravity about 1.05. Sparingly soluble in water; sol- tions are similar to those of neostigmine (p.632) but much more bromid; Homatropini hydrobromidum; Homatropinium Bro- uble in alcohol and in vegetable oils. It is decomposed by mois- prolonged. Its miotic action begins within 1 hour of its applica- mide; Homatropino hidrobromidas; Homatropinum Bromatum; ture with the evolution of hydrogen fluoride.
    [Show full text]
  • Pharmacology of Ophthalmologically Important Drugs James L
    Henry Ford Hospital Medical Journal Volume 13 | Number 2 Article 8 6-1965 Pharmacology Of Ophthalmologically Important Drugs James L. Tucker Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Chemicals and Drugs Commons, Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Tucker, James L. (1965) "Pharmacology Of Ophthalmologically Important Drugs," Henry Ford Hospital Medical Bulletin : Vol. 13 : No. 2 , 191-222. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol13/iss2/8 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. For more information, please contact [email protected]. Henry Ford Hosp. Med. Bull. Vol. 13, June, 1965 PHARMACOLOGY OF OPHTHALMOLOGICALLY IMPORTANT DRUGS JAMES L. TUCKER, JR., M.D. DRUG THERAPY IN ophthalmology, like many specialties in medicine, encompasses the entire spectrum of pharmacology. This is true for any specialty that routinely involves the care of young and old patients, surgical and non-surgical problems, local eye disease (topical or subconjunctival drug administration), and systemic disease which must be treated in order to "cure" the "local" manifestations which frequently present in the eyes (uveitis, optic neurhis, etc.). Few authors (see bibliography) have attempted an introduction to drug therapy oriented specifically for the ophthalmologist. The new resident in ophthalmology often has a vague concept of the importance of this subject, and with that in mind this paper was prepared.
    [Show full text]
  • Order in Council 1243/1995
    PROVINCE OF BRITISH COLUMBIA ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL Order in Council No. 12 4 3 , Approved and Ordered OCT 121995 Lieutenant Governor Executive Council Chambers, Victoria On the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and consent of the Executive Council, orders that Order in Council 1039 made August 17, 1995, is rescinded. 2. The Drug Schedules made by regulation of the Council of the College of Pharmacists of British Columbia, as set out in the attached resolution dated September 6, 1995, are hereby approved. (----, c" g/J1"----c- 4- Minister of Heal fandand Minister Responsible for Seniors Presidin Member of the Executive Council (This pan is for adnwustratlye purposes only and is not part of the Order) Authority under which Order Is made: Act and section:- Pharmacists, Pharmacy Operations and Drug Scheduling Act, section 59(2)(1), 62 Other (specify): - Uppodukoic1enact N6145; Resolution of the Council of the College of Pharmacists of British Columbia ("the Council"), made by teleconference at Vancouver, British Columbia, the 6th day of September 1995. RESOLVED THAT: In accordance with the authority established in Section 62 of the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia, S.B.C. Chapter 62, the Council makes the Drug Schedules by regulation as set out in the attached schedule, subject to the approval of the Lieutenant Governor in Council. Certified a true copy Linda J. Lytle, Phr.) Registrar DRUG SCHEDULES to the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia The Drug Schedules have been printed in an alphabetical format to simplify the process of locating each individual drug entry and determining its status in British Columbia.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]